Actively Recruiting
Phase 1 Study Evaluating Safety and Pharmacokinetics of Intravesical UGN-501 in Adults with Recurrent Non-Muscle Invasive Bladder Cancer
Led by UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. · Updated on 2026-10-13
30
Participants Needed
15
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, immune response, and pharmacokinetics of UGN-501, a chimeric oncolytic adenovirus, given directly into the bladder for adults with recurrent non-muscle invasive bladder cancer NMIBC. This Phase 1, open-label, dose-escalation study focuses on participants with high-grade and low-grade Ta andor T1 disease or carcinoma in situ CIS, aiming to find the recommended dose for further study. Participants will undergo a 12-week Induction Period with six weekly intravesical instillations of UGN-501. Those with certain disease types who respond or do not have recurrence will continue into a Maintenance Period, receiving three weekly instillations every three months from Month 3 to Month 12. Disease assessments occur every three months up to 15 months or until recurrence, progression, or death. The study may add other intervention arms or dose expansions in future amendments. During the study, participants will have regular evaluations including monitoring for dose-limiting toxicities, adverse events, drug levels in blood and urine, and immune response. Disease status will be assessed at specified intervals, with follow-up lasting up to 15 months. The main outcomes measured include safety, complete response rate at 3 months, and recurrence-free survival at 6 months, along with detailed pharmacokinetic and viral shedding analyses.
CONDITIONS
Brief Title
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
Research Team
H
Heather Lansford
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here